Category: vorasidenib
-
Agios to receive $1.1B in milestone payments for vorasidenib approval (NASDAQ:AGIO)
•
study Agios PharmaceuticalsNASDAQ: AGIWAmerican drugmaker ABM said it will receive $1.1 billion in milestone payments after the U.S. Food and Drug Administration approved its drug furasidinib to treat malignant brain tumors. The biotech company said it will receive $905 million from Royalty Pharma in connection with its recent royalty agreement.…